These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 203289)

  • 1. Soluble dextran complexes of kallikrein. Bradykinin and enzyme inhibitors.
    Odya CE; Levin Y; Erdös EG; Robinson CJ
    Biochem Pharmacol; 1978 Jan; 27(2):173-9. PubMed ID: 203289
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of covalent binding of aprotinin with a polysaccharide carrier on its inhibition of kallikrein from human plasma, porcine pancreatic kallikrein and trypsin].
    Larionova NI; Makevnina LG; Nartikova VF; Paskhina TS
    Biokhimiia; 1987 May; 52(5):825-31. PubMed ID: 2439135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological activity of an amino analogue of a tripeptide inhibitor of angiotensin-converting enzyme.
    Almquist RG; Christie PH; Chao WR; Johnson HL
    J Pharm Sci; 1983 Jan; 72(1):63-7. PubMed ID: 6298401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent antihypertrophic effect of the bradykinin B2 receptor system on the renal vasculature.
    Tsuchida S; Miyazaki Y; Matsusaka T; Hunley TE; Inagami T; Fogo A; Ichikawa I
    Kidney Int; 1999 Aug; 56(2):509-16. PubMed ID: 10432390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinins mediate kallikrein-induced endothelium-dependent relaxations in isolated canine coronary arteries.
    Mombouli JV; Vanhoutte PM
    Biochem Biophys Res Commun; 1992 Jun; 185(2):693-7. PubMed ID: 1376991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of angiotensin-converting enzyme.
    Cushman DW; Ondetti MA
    Prog Med Chem; 1980; 17():41-104. PubMed ID: 6273970
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of bradykinin, kallikrein and its inhibitor on haematological indices of peripheral blood in rabbits.
    Mietkiewski E; Danieyko-Osman M
    Acta Physiol Pol; 1979; 30(2):305-12. PubMed ID: 313660
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of the angiotensin I converting enzyme of the lung by a peptide fragment of bradykinin.
    Oshima G; Erdös EG
    Experientia; 1974 Jul; 30(7):733-4. PubMed ID: 4367995
    [No Abstract]   [Full Text] [Related]  

  • 9. Kallikreins and their inhibitors in various tissues.
    Hori S; Masumura S; Mizuta K; Kondo M
    Mie Med J; 1969 Jan; 18(3):223-33. PubMed ID: 5308357
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of activators and inhibitors of the kallikrein-kinin system on adrenergic responses of the heart and vessels].
    Rzaev NM; Abaskulieva LI; Khanumova TA; Akhverdiev TG
    Fiziol Zh SSSR Im I M Sechenova; 1977 Mar; 63(3):429-33. PubMed ID: 301104
    [No Abstract]   [Full Text] [Related]  

  • 11. [Bradykinin-potentiating peptides from the spider Latrodectus tredecimguttatus--inhibitors of carboxycathepsin and of a preparation of karakurt venom kininase].
    Sosnina NA; Golubenko Z; Akhunov AA; Kugaevskaia EV; Eliseeva IuE; Orekhovich VN
    Dokl Akad Nauk SSSR; 1990; 315(1):236-9. PubMed ID: 1965800
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthetic inactivators of kallikrein.
    Shaw E
    Adv Exp Med Biol; 1983; 156():339-45. PubMed ID: 6190371
    [No Abstract]   [Full Text] [Related]  

  • 13. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
    Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
    J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developmental regulation of ACE gene expression by endogenous kinins and angiotensin II.
    Yosipiv IV; el-Dahr SS
    Am J Physiol; 1995 Aug; 269(2 Pt 2):F172-9. PubMed ID: 7544538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.
    van Esch JH; Tom B; Dive V; Batenburg WW; Georgiadis D; Yiotakis A; van Gool JM; de Bruijn RJ; de Vries R; Danser AH
    Hypertension; 2005 Jan; 45(1):120-5. PubMed ID: 15583077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Differentiation of the oxytocic action in vitro of trasylol and kallikrein].
    Baraldi M
    Boll Soc Ital Biol Sper; 1969 Apr; 45(7):436-8. PubMed ID: 5307852
    [No Abstract]   [Full Text] [Related]  

  • 17. Tonin and kallikrein-kinin system.
    Feitosa MH; Pesquero JL; Ferreira MA; Oliveira GM; Rogana E; Beraldo WT
    Adv Exp Med Biol; 1989; 247A():573-80. PubMed ID: 2557755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration by kallikrein and bradykinin of the conversion of angiotensin I to angiotensin II in the isolated perfused rat lung.
    Ercan ZS; Bor NM; Torunoğlu M; Türker RK
    Arzneimittelforschung; 1982; 32(1):30-1. PubMed ID: 6174131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin I-converting enzyme from guinea pig lung and serum. A comparison of some kinetic and inhibition properties.
    Lanzillo JJ; Fanburg BL
    Biochim Biophys Acta; 1976 Aug; 445(1):161-8. PubMed ID: 182273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The angiotensin I converting enzyme.
    Erdös EG
    Fed Proc; 1977 Apr; 36(5):1760-5. PubMed ID: 191298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.